Anti-TNFRSF8 (Brentuximab-LC-N152)-DBCO-MMAF ADC

This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (Brentuximab variant,LC-N152) conjugated via a DBCO linker to MMAF. The MMAF is targeted to ceRoom Temperatureain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.